1AI Stock Overview
A biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Algorae Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0075 |
| 52 Week High | AU$0.014 |
| 52 Week Low | AU$0.0065 |
| Beta | 0.73 |
| 11 Month Change | -6.25% |
| 3 Month Change | -31.82% |
| 1 Year Change | -50.00% |
| 33 Year Change | -31.81% |
| 5 Year Change | -60.53% |
| Change since IPO | -85.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1AI | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 7.1% | -0.8% | 1.2% |
| 1Y | -50.0% | 13.9% | 10.6% |
Return vs Industry: 1AI underperformed the Australian Biotechs industry which returned 13.9% over the past year.
Return vs Market: 1AI underperformed the Australian Market which returned 10.6% over the past year.
Price Volatility
| 1AI volatility | |
|---|---|
| 1AI Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: 1AI's share price has been volatile over the past 3 months.
Volatility Over Time: 1AI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | David Hainsworth | www.algoraepharma.com |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer’s disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.
Algorae Pharmaceuticals Limited Fundamentals Summary
| 1AI fundamental statistics | |
|---|---|
| Market cap | AU$11.81m |
| Earnings (TTM) | -AU$2.10m |
| Revenue (TTM) | AU$125.20k |
94.3x
P/S Ratio-5.6x
P/E RatioIs 1AI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AI income statement (TTM) | |
|---|---|
| Revenue | AU$125.20k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$125.20k |
| Other Expenses | AU$2.22m |
| Earnings | -AU$2.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,673.77% |
| Debt/Equity Ratio | 0% |
How did 1AI perform over the long term?
See historical performance and comparison